KMT2A and acute lymphoblastic leukemia: We previously targeted the proteotoxic stress of MLL-rearranged (MLL-r) leukemia with bortezomib, and the proteasome inhibitor displayed selective killing in acute lymphoblastic leukemia but nonspecific toxicity to AML cells, revealing that oncogene might exert different stress on distinct cell types [11].